Erratum to: Influence of Telmisartan on Insulin Response after Glucose Loading in Obese Patients with Hypertension: ARB Trial of Hypertension in Obese Patients with Hyperinsulinemia Assessed by Oral Glucose Tolerance Test (ATHLETE)

Yutaka Mori · Takaaki Tanaka · Kenichi Matsuura · Junichi Yokoyama · Kazunori Utsunomiya

© Springer Healthcare 2012

Erratum to: Mori Y, Tanaka T, Matsuura K, Yokoyama J, Utsunomiya K. Influence of Telmisartan on Insulin Response after Glucose Loading in Obese Patients with Hypertension: ARB Trial of Hypertension in Obese Patients with Hyperinsulinemia Assessed by Oral Glucose Tolerance Test (ATHLETE). Adv Ther. 2011;28(8):698-706.

The authors of the above-mentioned paper noticed a few errors in the tables and figures, as reported. In Table 1, the ‘group treated with the current ARB’ BMI score should read 26.6 ± 2.2 , and not 26.6 ± 1.9 , as reported. Also, the BMI max-min scores for both groups should read 33.0–23.6 (telmisartan group) and 30.6–24.5 (ARB group), not 25.0–31.3 and 25.0–30.6, as reported. In Table 2, the baseline HbA1c result for the current ARB group should read 5.66 ± 0.52 , and not 5.56 ± 0.52 , and the 6 month LDL cholesterol result for the telmisartan group should read 109.6 ± 30.0 , not 109.6 ± 30.3 , as reported. In Figure 1A the P value should be $P < 0.05$, not $P = 0.05$. In Figures 1 and 2, the x axis values were slightly incorrect; the correct figures are shown below. The authors regret the errors, and thank Springer Healthcare for publishing the correction.

Figure 1. Blood glucose (A) and insulin (B) response in the telmisartan group using the 75 g oral glucose tolerance test (OGTT). Statistical test=the signed rank sum test.

Figure 2. Blood glucose (A) and insulin (B) response in the current angiotensin II receptor blocker (ARB) group using the 75 g oral glucose tolerance test (OGTT). Statistical test=the signed rank sum test.

Table 1. Patient background.

	Group switching to telmisartan	Group treated with the current ARB
Number of patients	14	14
Male/female	4/10	6/8
Age, years	69.1±5.3	67.6±5.9
BMI, kg/m ² (max-min)	27.6±3.1 (33.0-23.6)	26.6±2.2 (30.6-24.5)
HbA1c, %	5.58±0.48	5.66±0.52
Previous ARB, <i>n</i>		
Valsartan 80 mg	3	3
Candesartan 8 mg	11	11

ARB=angiotensin II receptor blocker; BMI=body mass index; HbA1c=hemoglobin A1c.

Table 2. Changes in blood pressure, BMI, HbA1c, and serum lipid levels.

Evaluation item	Telmisartan group			Current ARB group		
	Baseline	6 months	<i>P</i> -value	Baseline	6 months	<i>P</i> -value
Systolic blood pressure, mmHg	130.4±5.3	129.7±5.6	NS	128.7±5.8	129.7±5.6	NS
Diastolic blood pressure, mmHg	81.0±5.8	81.4±5.8	NS	81.4±5.5	84.0±3.9	NS
BMI, kg/m ²	27.6±3.1	27.5±3.2	NS	26.6±2.2	26.6±1.9	NS
HbA1c, % (JDS)	5.58±0.48	5.56±0.49	NS	5.66±0.52	5.74±0.57	NS
Total cholesterol, mg/dL	202±25	201±28.5	NS	204±28.4	202±36.3	NS
LDL cholesterol, mg/dL	112.3±27.5	109.6±30.0	NS	118.3±27	117.8±30.5	NS
HDL cholesterol, mg/dL	63.4±14.7	69±13	NS	59.4±18.3	56.9±16.2	NS
Triglycerides, mg/dL	130±45.6	113±36.8	NS	133±49.2	136±47.9	NS

ARB=angiotensin II receptor blocker; BMI=body mass index; HbA1c=hemoglobin A1c; HDL=high-density lipoprotein; JDS=Japanese Diabetes Society; LDL=low-density lipoprotein; NS=not significant (using the signed rank sum test).